Scientists at the Paul Scherrer Institute PSI have refined an X-ray diffraction technique for detecting biological structures ...

Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 ...

Biological materials are masterpieces created by nature. Bones, for example, are extremely hard, yet at the same time elastic ...

Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...

According to MarketsandMarkets, the services NDT and inspection market is expected to grow from USD 11.41 billion in 2025 to ...

Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains.

America's national security relies in part on the U.S. Navy's nuclear-powered submarines, which can operate more than 800 ...

The data illustrate that several patients remained on zenocutuzumab well beyond progression, including multiple patients who continued treatment for more than one- or two-years post-progression.

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss ...

The Institut national de la recherche scientifique (INRS) and Infinite Potential Laboratories (IPL) have reached a historic ...